Century Therapeutics Inc. (IPSC)
0.50
0.00 (0.16%)
At close: Apr 15, 2025, 3:59 PM
0.47
-4.90%
After-hours: Apr 15, 2025, 05:50 PM EDT
0.16% (1D)
| Bid | 0.48 |
| Market Cap | 42.98M |
| Revenue (ttm) | 6.59M |
| Net Income (ttm) | -126.57M |
| EPS (ttm) | -1.61 |
| PE Ratio (ttm) | -0.31 |
| Forward PE | -0.46 |
| Analyst | Buy |
| Ask | 0.49 |
| Volume | 292,080 |
| Avg. Volume (20D) | 493,336 |
| Open | 0.51 |
| Previous Close | 0.50 |
| Day's Range | 0.47 - 0.54 |
| 52-Week Range | 0.34 - 3.70 |
| Beta | 1.84 |
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting C...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol IPSC
Website https://www.centurytx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 300.40% from the latest price.
Stock ForecastsNext Earnings Release
Century Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
